Almotriptan in the acute treatment of migraine in patients 11-17 years old: An open-label pilot study of efficacy and safety

被引：18

作者：

Charles J.A. ^{[1
]}

机构：

[1] Department of Neurosciences, New Jersey Medical School, Newark, NJ 07103-2714

来源：

The Journal of Headache and Pain | 2006年 / 7卷 / 2期

关键词：

Adolescent; Almotriptan; Children; Migraine; Triptan;

D O I：

10.1007/s10194-006-0288-0

中图分类号：

学科分类号：

摘要：

The objective was to investigate the safety and efficacy of almotriptan in patients aged 11-17 years old with acute migraine. Fifteen patients aged 11-17 with a history of migraine with or without aura were treated with almotriptan. Reduction in headache severity, disability and adverse effects were studied. Almotriptan in doses ranging from 6.25 to 12.5 mg was well tolerated. There were virtually no adverse effects except for one case of transient mild stiffness. Of the 15 patients, only 2 demonstrated no efficacy without adverse effects. In the other 13 patients, not only was almotriptan effective, but again, no significant adverse effects were reported. Almotriptan is probably safe and effective in patients aged 11-17. This small open-label pilot study should support the feasibility of a large randomised controlled study to demonstrate tolerability and efficacy of almotriptan in children and adolescents with episodic migraine. © Springer-Verlag Italia 2006.

引用

页码：95 / 97

页数：2

共 10 条

[1]

Abu-Arefeh I., Russell G., Prevalence of headache and migraine in school children, BMJ, 309, pp. 765-769, (1994)

[2]

Linet M.S., Stewart W.F., Celentano D.D., Ziegler D., Sprecher M., An epidemiologic study of headache among adolescents and young adults, JAMA, 261, pp. 2211-2216, (1989)

[3]

Winner P., Rothner A.D., Saper J., Et al., A randomized double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents, Pediatrics, 106, pp. 989-997, (2000)

[4]

Hershey A., Powers S.W., LeCates S., Bentti A.L., Effectiveness of nasal sumatriptan in 5 to 12-year-old children, Headache, 41, pp. 693-697, (2001)

[5]

Winner P., Lewis D., Visser W.H., Et al., Rizatriptan 5 mg for the acute treatment of migraine in adolescents: A randomized double-blind, placebo-controlled study, Headache, 42, pp. 49-55, (2002)

[6]

Rothner A.D., Wasiewski W., Winner P., Lewis D., Stankowski J., Zolmitriptan oral tablet in migraine treatment: High placebo responses in adolescents, Headache, 46, pp. 101-109, (2006)

[7]

Rothner A., Edwards K., Kerr L., DeBussey S., Asgharnejhad M., Efficacy and safety of naratriptan tablets in adolescent migraine, J Neurol Sci, 150, SUPPL. 1, (1997)

[8]

Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J., Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials, Lancet, 358, pp. 1668-1675, (2001)

[9]

Goadsby P.J., Lipton R.B., Ferrari M.D., Migraine - Current understanding and treatment, N Engl J Med, 346, pp. 257-270, (2002)

[10]

Goadsby P.J., Lipton R.B., Ferrari M.D., Physicians desk reference, (2005)

← 1 →